The slight decline. After the end of the trading on the 19th, it disclosed the development status of the clinical trial using 'DFP-17729' for end-stage pancreatic cancer patients in Japan. As a result of the stratified analysis combining Phase 1 and Phase 2, the median overall survival (mOS) in the experimental drug group was 9.0 months, and the median overall survival (mOS) in the control group was 6.1 months, with a difference between the two groups. However, it seems to be affected by the decline of Sun Bio, etc. which are positive news.
ＤＥＬＴＡ－Ｐ---小幅下落、「DFP-17729」開発状況良好も
Delta-P slightly decreased, development of DFP-17729 is good.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.